Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce alcohol intake in animal models. To further investigate this effect, a real-world study evaluated the effectiveness of liraglutide and semaglutide in reducing alcohol use among 262 patients (79% female; mean age: 46 years) with a BMI ³ 27 kg/m2. The study found that liraglutide and semaglutide reduced alcohol consumption from 11.8 units/week to 4.3 units/week. Notably, GLP-1 RAs led to a 68% reduction in alcohol intake among regular drinkers.
This reduction is comparable to the 61% decrease in alcohol intake observed with nalmefene, a medication approved for treating alcohol use disorder. These findings suggest that GLP-1 RAs may have a therapeutic role in reducing alcohol consumption in individuals with obesity. Did you find this article interesting? ##Reference## Farrell MO, Almohaileb FI, le Roux CW.…
